Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q3 FY23 results · Oct–Dec 2022
Solara Active Pharma Sciences reported revenue from operations of ₹394.75 crore (up 293.4% from Q3 FY22) and net profit of ₹0.43 crore for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 394.75 | 100.34 | +293.4% | 338.37 | +16.7% |
| Other income | 7.17 | 4.73 | +51.6% | 3.72 | +92.7% |
| Total income | 401.92 | 105.07 | +282.5% | 342.09 | +17.5% |
| Profit before tax | 0.55 | (139.89) | Turned profit | (19.30) | Turned profit |
| Net profit for the period | 0.43 | (139.89) | Turned profit | (9.98) | Turned profit |
| Attributable to shareholders of the company | 0.45 | (139.87) | Turned profit | (9.96) | Turned profit |
| EPS, basic (₹) | 0.12 | (38.93) | Turned profit | (2.77) | Turned profit |
| Net margin (%) | 0.1 | -139.4 | -2.9 |
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 394.75 | 100.34 | +293.4% | 338.37 | +16.7% |
| Other income | 6.77 | 4.76 | +42.2% | 3.77 | +79.6% |
| Total income | 401.52 | 105.10 | +282.0% | 342.14 | +17.4% |
| Profit before tax | 0.53 | (139.57) | Turned profit | (19.23) | Turned profit |
| Net profit for the period | 0.42 | (139.57) | Turned profit | (9.91) | Turned profit |
| EPS, basic (₹) | 0.12 | (38.85) | Turned profit | (2.75) | Turned profit |
| Net margin (%) | 0.1 | -139.1 | -2.9 |
Consolidated
- Filed with BSE
- 25 Jan 2023, 16:50 IST
- Board meeting
- 25 Jan 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 25 Jan 2023, 16:50 IST
- Board meeting
- 25 Jan 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE